Editorial
The NeoRes trial: questioning the benefit of radiation therapy as part of neoadjuvant therapy for esophageal adenocarcinoma
Abstract
The “optimal” multimodality treatment for locally advanced esophageal cancer has seemingly been defined by the CROSS (Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study) trial, with proponents arguing that neoadjuvant chemoradiation is the standard of care (1).
